Share this video  

SABCS 2023 | Tumor immune architecture in TNBC

Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, highlights data of a Phase III trial (NCT00114816) evaluating the outcomes and characteristics of patients with triple-negative breast cancer (TNBC) with one of three immune landscape architectures based on the locations of stromal tumor-infiltrating lymphocytes (sTILs) – namely immune enriched (IN), immune excluded (IE), and immune desert (ID). The study showed that patients with IE tumors had poor outcomes despite having high TILs, and a more in-depth analysis noted the central role of plasmacytoid dendritic cells and IFN-alpha in TNBC. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.